Veradermics (MANE) Jefferies Global Healthcare Conference 2026 summary

Market opportunity and unmet need

• Pattern hair loss affects 80 million people in the U.S., with 50 million men and 30 million women, making it far more prevalent than other dermatological conditions.

• Only 9% of patients are satisfied with current treatments, and nearly 50% are actively seeking new options due to slow onset, inconsistent results, and insufficient hair density.

• There are no FDA-approved oral treatments for female pattern hair loss, representing a significant unmet need and opportunity.

• 20 million patients are identified as immediate launch targets, including those on prescription, OTC, or showing high digital intent to seek treatment.

• Market research shows high intent to adopt the new product among both physicians and patients, with strong differentiation from existing options.

Clinical trial results and product profile

• Study 302, a phase II/III trial in 500 males, showed statistically significant improvements in both hair count and patient-reported outcomes.

• Up to 86% of patients reported improvement, with visible hair regrowth as early as two months and a strong tolerability profile similar to placebo.

• No treatment-related serious adverse events or cardiac issues were observed, and no hair shedding was reported after treatment initiation.

• Both patients and investigators reported consistent and meaningful improvements, changing the treatment conversation from stabilization to likely hair growth.

• The product is positioned to be the first FDA-approved oral treatment for male pattern hair loss in 30 years.

Commercial strategy and market adoption

• Market segmentation identifies 3 million current prescription users, 10 million OTC users, and 7 million high-intent digital seekers as priority segments.

• Physicians indicated they would prescribe the new product to over 50% of their patients, a much higher rate than typical for new launches.

• Patients across all segments, including those not currently treating, showed strong intent to discuss the product with their doctors.

• Analogies to GLP-1s in obesity and Viagra in ED suggest potential for explosive market growth and rapid conversion from OTC to prescription.

• Commercialization will focus on HCP promotion, digital patient acquisition, and a patient-first distribution strategy to reduce friction.